{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021244","form_type":"8-K","ticker":"CLYM","cik":"0001768446","company_name":"Climb Bio, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.468990+00:00","generated_at":"2026-06-15T04:28:04.854757+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Eliem Therapeutics Q1 net loss $22.3M; cash $109.4M funds operations into 2027","bullets":["Net loss of $22.3M for Q1 2023 vs $13.2M in Q1 2022; includes $15.8M restructuring costs.","Cash, cash equivalents and marketable securities $109.4M as of March 31, 2023.","Presented initial preclinical data for lead Kv7 candidate ETX-123; IND-enabling studies initiated.","Phase 1 clinical studies for ETX-123 planned to start in first half of 2024.","R&D expenses $5.7M, G&A expenses $17.7M (includes $14.0M restructuring costs)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021244","json":"https://secwatch.observer/filing/0000950170-23-021244.json","markdown":"https://secwatch.observer/filing/0000950170-23-021244.md","text":"https://secwatch.observer/filing/0000950170-23-021244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768446/000095017023021244/0000950170-23-021244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768446/000095017023021244/elym-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:28:04.854757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e569d97fec384ffd40f545b292ca9b7ca61ac86f","claim":"Climb Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $22.3 million.","evidence_excerpt":"Eliem Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768446/000095017023021244/0000950170-23-021244-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $22.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}